Bcal Diagnostics logo

Bcal Diagnostics(ASX) BDX

Market CapA$33.18MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-64%
5 Year-42%
1 Year+7%
1 Month+38%
A$0.09
+0.00%
+0.00Today
Bcal Diagnostics last closing stock price
MetricPriceDate
Last closeAUD 0.092026-10-09
Bcal Diagnostics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+3.45%AUD 0.092026-10-02
1 month+38.46%AUD 0.072026-09-08
3 month+23.29%AUD 0.072026-07-10
Year to date-14.29%AUD 0.112025-12-31
1 year+7.14%AUD 0.082025-10-09
3 year-7.22%AUD 0.102023-10-10
5 year-41.94%AUD 0.162021-10-08
Since inception-64%AUD 0.252021-07-21

Bcal Diagnostics Financials at a Glance

Market Cap

A$33.18MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$2.83M

Net Income (TTM)

-A$14.61M

EPS (TTM)

-A$0.02

P/E Ratio

-4.48

Dividend

A$0.00

Beta (Volatility)

0.11 (Low)

Price

A$0.09

Volume

104,931

Open

A$0.09

Previous Close

A$0.09

Daily Range

A$0.09 - A$0.09

52-Week Range

A$0.05 - A$0.16

Estimated Earnings Date

Feb 23, 2027

BDX News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Bcal Diagnostics

BCAL Diagnostics Limited is a biotechnology firm dedicated to developing an advanced, non-surgical laboratory blood test for breast cancer detection. The company's flagship product, the BCAL test, utilizes lipid biomarkers to facilitate early screening and ongoing patient monitoring.

Products and Services
  • BCAL test for breast cancer detection
  • In vitro diagnostic (IVD) technology
  • Research and development in lipid biomarker assays
Growth Outlook
  • Established in 2010, with a focus on innovative diagnostics
  • Potential market expansion as breast cancer screening becomes more prevalent
  • Increased investment in research and development to enhance product offerings
Financial Highlights
  • Recent quarterly revenue of AUD 139,892, showing growth potential
  • Trailing twelve months (TTM) revenue of AUD 1,394,195, indicating market interest
  • Cash and cash equivalents of AUD 1,586,720, providing operational liquidity
BCAL Diagnostics Limited operates in the medical diagnostics and research sector, focusing on innovative solutions for breast cancer detection. The BCAL test represents a significant advancement in non-invasive testing, which could transform breast cancer screening practices. The company has shown a commitment to research and development, which is crucial for maintaining a competitive edge in the biotechnology industry. The growth outlook for BCAL Diagnostics is promising, with the potential for market expansion as awareness and demand for breast cancer screening increase. The company's focus on lipid biomarker assays positions it well within the evolving landscape of medical diagnostics. Recent financial data indicates a growing interest in the company's offerings, with a notable revenue increase in the latest quarter. Investors may find BCAL Diagnostics Limited an intriguing opportunity, given its innovative approach to breast cancer detection and the potential for future growth in a critical healthcare sector.
AI Generated • Sep 23, 2026

Industry

Biotechnology

Sector

Health Care

CEO

Anne-Louise Arnett

Website

www.bcaldiagnostics.com

Headquarters

Sydney, NSW 2000, AU

BDX Financials

Key Financial Metrics (TTM)

Gross Margin

-292.98%

Operating Margin

-5145.88%

Net Income Margin

-4038.97%

Return on Equity

-881.94%

Return on Capital

-154.22%

Return on Assets

-96.21%

Earnings Yield

-22.32%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

A$33.18MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

368.68M

Volume

104.93K

Avg. Volume

128.47K

Financials (TTM)

Gross Profit

A$2.12M

Operating Income

-A$15.43M

EBITDA

-A$14.71M

Operating Cash Flow

-A$12.30M

Capital Expenditure

-A$1.25M

Free Cash Flow

-A$13.54M

Cash & ST Invst.

A$1.59M

Total Debt

A$6.92M

Bcal Diagnostics Performance Analysis

Bcal Diagnostics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 0N/A
20242024-06-30AUD 0N/A
20252025-06-30AUD 21,637N/A
20262026-06-30AUD 182,510743.5%
Bcal Diagnostics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3116.9%
Q42025-06-30-8.7%
Q22025-12-31-96.6%
Q42026-06-30228.2%
Bcal Diagnostics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.0244.6%
20242024-06-30AUD -0.038.3%
20252025-06-30AUD -0.02-22.7%
20262026-06-30AUD -0.020.0%
Bcal Diagnostics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-31N/A
Q42025-06-3039.9%
Q22025-12-31-16.3%
Q42026-06-3012.1%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$139.89K

-88.2%

Gross Profit

-A$185.47K

-115.0%

Gross Margin

-1.33%

N/A

Market Cap

A$33.18MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

A$5.53M

N/A

Employees

6

N/A

Net Income

-A$3.45M

+13.5%

EBITDA

-A$4.05M

-15.7%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$1.59M

-75.5%

Total Debt

A$6.92M

+353.8%

Accounts Receivable

A$2.38M

+6785.6%

Inventory

A$0.00

N/A

Long Term Debt

A$5.13M

+374.3%

Short Term Debt

A$1.79M

+303.9%

Return on Assets

-96.21%

N/A

Return on Invested Capital

-2.02%

N/A

Free Cash Flow

-A$3.67M

+21.2%

Operating Cash Flow

-A$3.66M

-0.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MAP.AXMicroba Life Sciences Limited
A$0.05+2.00%
EYE.AXNova Eye Medical Limited
A$0.14+0.00%
RHY.AXRhythm Biosciences Limited
A$0.08+4.17%
EMD.AXEmyria Limited
A$0.04+2.44%

Trending Stocks

Symbol / CompanyPricePrice Chg
TAT&T
$22.18-9.81%
WFFWf
$12.29+499.51%
VZVerizon Communications
$41.65-8.75%
SPCXSpace Exploration Technologies
$162.57+1.25%

Questions About BDX

What is the current price of Bcal Diagnostics?

Bcal Diagnostics is trading at A$0.09 per share.

What is the 52-week range for Bcal Diagnostics?

Over the past 52 weeks, Bcal Diagnostics has traded between A$0.05 and A$0.16.

How much debt does Bcal Diagnostics have?

As of the most recent reporting period, Bcal Diagnostics reported total debt of A$6.92M.

How much cash does Bcal Diagnostics have on hand?

Bcal Diagnostics reported A$1.59M in cash and cash equivalents in its most recent financial results.

What is Bcal Diagnostics’s dividend yield?

Bcal Diagnostics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services